With 0.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.72 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $22.3 whereas the lowest price it dropped to was $21.695. The 52-week range on RCKT shows that it touched its highest point at $32.53 and its lowest point at $14.89 during that stretch. It currently has a 1-year price target of $49.33. Beta for the stock currently stands at 1.11.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RCKT was down-trending over the past week, with a drop of -3.60%, but this was down by -19.34% over a month. Three-month performance dropped to -22.19% while six-month performance rose 21.98%. The stock gained 25.39% in the past year, while it has lost -26.66% so far this year. A look at the trailing 12-month EPS for RCKT yields -2.94 with Next year EPS estimates of -1.81. For the next quarter, that number is -0.67. This implies an EPS growth rate of 10.22% for this year and 31.03% for next year. EPS is expected to grow by 41.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.09%.
Float and Shares Shorts:
At present, 90.28 million RCKT shares are outstanding with a float of 83.98 million shares on hand for trading. On 2024-04-15, short shares totaled 11.0 million, which was 1216.0 higher than short shares on 1710460800. In addition to Dr. Gaurav D. Shah M.D. as the firm’s CEO & Director, Ms. Kinnari Patel M.B.A., Pharm.D. serves as its Head of R&D, President & COO.
Institutional Ownership:
Through their ownership of 1.0141101 of RCKT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, RCKT reported revenue of $0.0 and operating income of -$63279000.0. The EBITDA in the recently reported quarter was -$57255000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RCKT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
